inVentiv's Otis Johnson Joins Site Optics and Quality Informatics Steering Committee for Development of Industry Wide Site-Based Performance Metrics and Informatics Standards
inVentiv Clinical Trial Recruitment Solutions (iCTRS), created to accelerate trials, and the Alliance for Clinical Research Excellence and Safety (ACRES), an Alliance-driven non-profit organization operating in the public interest and dedicated to enhancing quality, safety, integrity and operational effectiveness in drug development and health research, are partnering to fast-track the development of a global system to support responsible conduct of clinical trials according to the highest standards of safety, quality and efficiency.
Numerous challenges limit the pace of progress for global clinical research. According to ACRES, the industry squanders $20 billion annually due to inefficiencies inherent to the current process of bringing a new drug to market. Uniform global standards for research sites and independent third-party accreditation are lacking, as are interconnectivity and interoperability. Standards support the objective identification and assessment of sites, delivering improved system management and long-term sustainability.
The partnership between ACRES and inVentiv focuses on developing and adopting global standards and performance metrics as the basis for clinical research best practices and guidelines, to encourage operational excellence. iCTRS brings expertise in global, data-driven decision support systems, advanced informatics technologies and a patient-centric approach for trial acceleration.
To further augment the partnership, Otis Johnson, Vice President of Clinical Research Services at iCTRS, will join the Steering Committee of ACRES' Site Optics and Quality Informatics Initiative (SOQI), focused on the development of a global information platform for effective trial management. The open access infrastructure will offer a collaborative network housing a massive data repository for worldwide data exchange. Johnson, a recognized thought leader in the industry, brings innovative solutions and thorough understanding of responsible 'big data' management and analytics, critical to the new system.
"iCTRS brings the clinical experience and global capabilities needed to help facilitate a comprehensive information management strategy necessary for the development of a global system," says Dr. Greg Koski, President and CEO of ACRES. "We look forward to Mr. Johnson joining the SOQI initiative, and leveraging his extensive clinical research, development and operations expertise."
"We're excited to join the ACRES Global Network as they set the standard for clinical excellence measures that will transform the industry," said Otis Johnson. "Together we'll promote new standards worldwide by creating awareness, building strategic industry alliances and raising the bar for clinical research sites."
As part of inVentiv Health, iCTRS' innovative capabilities to recruit and retain patients, draws upon expertise from over a dozen inVentiv Health business units that focus on the development and commercialization of drugs and other medical products for the life sciences industry. inVentiv Health has directly supported the development and/or commercialization of 60% of all drugs approved by the FDA in the last 5 years.
"inVentiv Health, with their extensive network of biopharmaceutical service companies worldwide, shares our vision of raising the standard of excellence," Koski added.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.
2 Commerce Drive
Cranbury, NJ 08512